TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01687959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tissue sampling from peritoneum of the gallbladder
Description: tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tissue sampling from peritoneum of the gallbladder
Description: tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
Study: NCT02605707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous stem cell transplantation
Description: Intravenous injection of autologous endothelial progenitor cells transplantation
Study: NCT02945033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin intake
Description: Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intake
Description: Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of colonic adenocarcinoma stage III or II high risk
Description: Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical resection of colonic adenocarcinoma stage III or II high risk
Description: Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Molecular analysis of exon 9 and 20 of PI3K
Description: Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Molecular analysis of exon 9 and 20 of PI3K
Description: Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood intake
Description: Blood intake will be done every 6 months to evaluate patient compliance to treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood intake
Description: Blood intake will be done every 6 months to evaluate patient compliance to treatment
Study: NCT01834014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT00334360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No drugs given during controlled hypothermia
Study: NCT01711281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)
Study: NCT01834014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT02090647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome
Study: NCT03939663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch pills manufactured to mimic misoprostol 200 mg tablets
Study: NCT03131804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic low intensity exercise
Description: Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
Study: NCT04290143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colored healing water
Description: Patients will be treated with colored healing water for 20 minutes.
Study: NCT02090647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic outcome
Study: NCT04385667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel intrauterine system (LNG-IUD)
Description: progestin delivery for regression of atypical endometrial hyperplasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Megesterol 160 mg daily
Description: progestin delivery for regression of atypical endometrial hyperplasia
Study: NCT04252924

Intervention type: OTHER
Intervention: lifestyle characteristics
Description: Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
Study: NCT05823389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-instrumentation with flapless Emdogain application
Description: Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-instrumentation with placebo application
Description: Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
Study: NCT04236440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (A1)
Description: 160 μg BAY2586116 (nasal spray administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (A1)
Description: 160 μg BAY2586116 (nasal spray administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (A2)
Description: Placebo matching BAY2586116 (nasal spray administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (A2)
Description: Placebo matching BAY2586116 (nasal spray administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B1)
Description: 160 μg BAY2586116 (nasal drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B1)
Description: 160 μg BAY2586116 (nasal drops)
Study: NCT03372252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
Study: NCT04497545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luna EMG
Description: The duration of the overall therapeutic intervention in both groups will be the same.

Intervention type: DEVICE
Group type: OTHER
Intervention: lower limb rotor
Description: The duration of the overall therapeutic intervention in both groups will be the same.
Study: NCT01052766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT and BH PET/CT
Description: First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
Study: NCT04923724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: tourniquet is a device used during total knee surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No tourniquet
Description: tourniquet is a device used during total knee surgery, this group does not get one
Study: NCT01414764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: 10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively
Study: NCT02499692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGYTM Coronary Stent System
Description: SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
Study: NCT03067493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-MASCT
Description: Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
Study: NCT00121394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal and infant wash
Study: NCT00386477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing before cesarean delivery
Description: Cleansing vagina with 1% betadine scrub before cesarean.
Study: NCT02830204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Replacement with Sapien3
Description: subjects with surgical MVR with Sapien3
Study: NCT03342040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral hernia repair with TAP block
Description: Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair without TAP block
Description: No block administered during Laparoscopic ventral hernia surgery
Study: NCT03421743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled molgramostim
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled molgramostim
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimycobacterial regimen
Description: Multidrug NTM guideline-based antimycobacterial regimen
Study: NCT00431951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246
Description: 250 mg, 400 mg or 800 mg capsules given once daily for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match experimental drug
Study: NCT02775331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift planning with self-rostering and shift ergonomics
Description: Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
Study: NCT00635609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (Doryx)
Description: 150mg/day, oral, delayed release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline hyclate
Description: 100 mg/day, oral, tablets, immediate release
Study: NCT04290143

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored healing water
Description: Patients will be treated with colored healing water for 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo treatment (colored tap water)
Description: Patients will be treated with colored tap water for 20 minutes.
Study: NCT01248442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
Study: NCT02085512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurocognitive retraining Web Based Intervention
Description: Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity.
Study: NCT02775331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shift planning with shift ergonomics
Description: Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
Study: NCT03455829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38
Description: CDK 4/6 inhibitor
Study: NCT01248442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02085512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, web-based tasks
Description: No training modules
Study: NCT03455829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg
Study: NCT01707303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early ICU rehabilitation strategies
Description: Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
Study: NCT03455829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFR TKI; 80 mg
Study: NCT01939132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label H.P. Acthar Gel
Description: Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
Study: NCT02182908

Intervention type: OTHER
Group type: OTHER
Intervention: PET-Scan
Description: PET-Scan
Study: NCT04412122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
Study: NCT01707303

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: All typically applied hospital rehabilitative services applied in the usual fashion
Study: NCT04638049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of human biofluids
Description: Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of human biofluids
Description: Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
Study: NCT04460066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-L1 antibody
Description: Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin bound paclitaxel
Description: Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albumin bound paclitaxel
Description: Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection of esophageal carcinoma
Description: Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: radical resection of esophageal carcinoma
Description: Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
Study: NCT00653185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT04236440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B2)
Description: 80 μg BAY2586116 (nasal spray)
Study: NCT02042248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
Study: NCT03359447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Ferrous Sulfate
Description: Drops
Study: NCT00653185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.